CLOs on the Move


 
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.abcuro.com
  • 90 Bridge Street Suite 100
    Newton, AB USA 02458
  • Phone: 617.714.9759

Executives

Name Title Contact Details

Similar Companies

Carmot Therapeutics

Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot`s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Glympse Bio

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.

Evidence CPR

EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses